Efficacy and Toxicity of Idarubicin Versus High-dose Daunorubicin for Induction Chemotherapy in Adult Acute Myeloid Leukemia: A Systematic Review and Meta- analysis Weerapat Owattanapanich, Natthida Owattanapanich, Smith Kungwankiattichai, Patompong Ungprasert, Theera Ruchutrakool Clinical Lymphoma, Myeloma and Leukemia Volume 18, Issue 12, Pages 814-821.e3 (December 2018) DOI: 10.1016/j.clml.2018.08.008 Copyright © 2018 The Authors Terms and Conditions
Figure 1 Flowchart Showing the Literature Review Process Abbreviations: HDD = high-dose daunorubicin; IDA = idarubicin. Clinical Lymphoma, Myeloma and Leukemia 2018 18, 814-821.e3DOI: (10.1016/j.clml.2018.08.008) Copyright © 2018 The Authors Terms and Conditions
Figure 2 Forest Plots Showing Odds Ratios Between High-dose Daunorubicin and Idarubicin Arms for the Response to Induction Therapy. (A) Complete Response Rate After First Induction Therapy; (B) Overall Complete Response Rate; and (C) Rate of Refractory Acute Myeloid Leukemia Abbreviations: CI = confidence interval; M-H = Mantel-Haenszel. Clinical Lymphoma, Myeloma and Leukemia 2018 18, 814-821.e3DOI: (10.1016/j.clml.2018.08.008) Copyright © 2018 The Authors Terms and Conditions
Figure 3 Forest Plots of Odds Ratios Between High-dose Daunorubicin and Idarubicin Arms for the Long-term Outcomes. (A) Overall Survival, (B) Event-free Survival, and (C) Cumulative Incidence of Relapse Abbreviations: CI = confidence interval; M-H = Mantel-Haenszel. Clinical Lymphoma, Myeloma and Leukemia 2018 18, 814-821.e3DOI: (10.1016/j.clml.2018.08.008) Copyright © 2018 The Authors Terms and Conditions
Figure 4 Forest Plots of Odds Ratios Between High-dose Daunorubicin and Idarubicin Arms for Treatment Complications. (A) Rate of Febrile Neutropenia After Induction Therapy; (B) Induction Mortality Rate; and (C) Cardiotoxicity Rate Abbreviations: CI = confidence interval; M-H = Mantel-Haenszel. Clinical Lymphoma, Myeloma and Leukemia 2018 18, 814-821.e3DOI: (10.1016/j.clml.2018.08.008) Copyright © 2018 The Authors Terms and Conditions
Supplemental Figure 1 Preferred Reporting Items for Systematic Reviews and Meta-Analyses Statement 2009 Checklist Clinical Lymphoma, Myeloma and Leukemia 2018 18, 814-821.e3DOI: (10.1016/j.clml.2018.08.008) Copyright © 2018 The Authors Terms and Conditions
Supplemental Figure 1 Preferred Reporting Items for Systematic Reviews and Meta-Analyses Statement 2009 Checklist Clinical Lymphoma, Myeloma and Leukemia 2018 18, 814-821.e3DOI: (10.1016/j.clml.2018.08.008) Copyright © 2018 The Authors Terms and Conditions